Kallisio’s Stentra wins CE mark for head and neck RT system
Kallisio has secured CE certification under the EU Medical Device Regulation for Stentra, its patient-specific intraoral positioning system for head and neck radiation therapy, opening the door to commercial sales in the European Economic Area. The March 25, 2026 announcement extends the company’s regulatory footprint beyond the U.S., where Stentra previously received FDA 510(k) clearance. (medicaleconomics.com)
Stentra is designed to address a familiar challenge in radiation oncology: keeping oral structures in a consistent, reproducible position across a treatment course while protecting healthy tissue near the target. According to Kallisio’s FDA-cleared indications, the device is intended for repeat positioning and immobilization of the tongue and jaw during external beam radiation therapy. FDA documents describe it as a custom-fitted polymeric oral stent that opens and immobilizes the jaw while deviating the tongue away from the radiation area. (accessdata.fda.gov)
That background helps explain why the CE mark matters. Kallisio has been positioning Stentra as a fully patient-specific alternative to prefabricated or semi-custom oral devices, using digital scanning, design automation, and rapid 3D printing. On its product site, the company says the device is simulation-ready, delivered within 72 hours, and built to integrate into existing clinical workflows without additional software. It also says the platform was co-developed with clinical experts at institutions including MD Anderson Cancer Center. (kallisio.com)
The European certification announcement adds a commercial dimension. Medical Economics, citing the company, reported that the CE certification clears Stentra for sale across the EEA and that Kallisio is offering a limited proof-of-value pilot program for interested clinics. In the same report, Stefan Rieken, director of radiation therapy and radiation oncology at Universitätsmedizin Göttingen, called Stentra “a significant advancement” for repeat positioning in head and neck radiation therapy and said he is particularly interested in its potential to reduce oral mucositis. (medicaleconomics.com)
There’s also a broader regulatory and product-development arc here. In January 2024, Kallisio announced FDA 510(k) clearance for Stentra in the U.S. FDA’s clearance summary shows the device was found substantially equivalent to a predicate oral stent for repeat positioning and immobilization during radiation therapy. The filing also notes non-clinical testing for biocompatibility, corrosion resistance, mechanical strength, and attenuation performance. That sequence, U.S. clearance followed by EU MDR certification, suggests Kallisio is moving from early regulatory validation toward wider commercial deployment. (businesswire.com)
Why it matters: For veterinary professionals, this isn’t a companion animal product launch, but it is relevant as a signal for where precision radiation support tools are heading. Veterinary radiation oncology also depends on highly reproducible setup, especially for anatomically complex head and neck tumors where sparing normal tissue is critical. A patient-specific oral immobilization approach could be conceptually relevant for specialty centers treating oral, nasal, or skull-adjacent tumors, even if translation into veterinary practice would require species-specific design, workflow validation, and its own regulatory and economic pathway. That’s an inference based on the device’s stated function in human care, not a current veterinary indication. (accessdata.fda.gov)
The business case may matter, too. Kallisio says Stentra is reimbursable in human medicine under existing CPT coding pathways, typically CPT 77334 for custom complex immobilization devices, and emphasizes that the system does not require changes to treatment-planning systems or IT infrastructure. For any radiation practice, human or veterinary, adoption of a custom device depends not just on clinical promise, but on whether it fits into simulation, fabrication, treatment, and reprocessing workflows without adding too much friction. (medicaleconomics.com)
What to watch: The next signals will be whether European pilot sites convert into routine clinical use, whether Kallisio publishes stronger outcomes data on toxicity reduction and setup reproducibility, and whether customized oral immobilization becomes a more standard expectation in head and neck radiation workflows. For veterinary teams, the bigger question is whether this kind of digitally manufactured, anatomy-specific support device remains a human oncology niche or starts to influence tool development in advanced animal cancer care. (medicaleconomics.com)